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Objectives: patients with peripheral arterial disease (PAD) have a threefold increase in cardiovascular mortality. Standard
antiplatelet treatment may not confer uniform benefit in different patient groups. This study aimed to compare platelet
function in patients with lower limb PAD, carotid disease and abdominal aortic aneurysm (AAA) with age- and
sex-matched healthy controls.
Methods: patients with lower limb PAD (n 20), carotid disease (n 40), AAA (n 13) and age/sex matched healthy
controls (n 20) were studied. Whole blood methods to detect spontaneous platelet aggregation (SPA), and adenosine
diphosphate (ADP) and collagen-induced aggregation were used. The detection of platelet P-selectin and the PAC-1 antigen
by flow cytometry were also used as markers of platelet activation and aggregation.
Results: patients with lower limb PAD or AAA had higher baseline SPA compared to normal controls (p < 0.01). There was
significantly higher collagen-induced aggregation in IC patients compared to normal controls (p < 0.01). However, there
was no difference in ADP-induced aggregation between lower limb PAD and control patients. There was no difference in
PAC-1 binding between control patients and the patients with lower limb PAD, carotid disease or AAA. Patients with
carotid disease had a higher expression of P-selectin compared to normal controls (p < 0.05).
Conclusions: this study provides further evidence that platelet hyperactivity is present in patients with PAD despite the
use of antiplatelet therapy. Further antiplatelet strategies may be indicated to protect these patients.
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Introduction
Activated platelets have been demonstrated in a wide
variety of clinical settings including peripheral arterial
disease (PAD) despite the use of aspirin.1±8 Patients
with intermittent claudication (IC) are at particular
risk of ischaemic episodes occurring in the peripheral,
coronary and cerebral circulation and the presence
of PAD is a strong indicator for systemic athero-
sclerosis.9±11 Compared with age-matched controls,
patients with IC have a threefold increase in cardio-
vascular mortality and although most patients are on
some form of antiplatelet treatment, its benefit seems
not to be uniform in different PAD patient groups.10±14
Antiplatelet therapy usually with aspirin (75±150 mg),
can reduce the risk of cardiovascular events.15,16
However platelet aggregation and thrombosis can still
occur in the presence of aspirin as there are other
important pathways for platelet activation that are
not affected by the blockade of cyclo-oxygenase.7,17,18
There may also be a group of patients resistant to
aspirin or with significant platelet hyperactivation
prior to any intervention despite being on antiplatelet
therapy.8,19,20 These patients may be at higher risk for
ischaemic complications. The aim of the current study
was to assess platelet function in a range of patients




Twenty control patients were studied to measure
baseline spontaneous platelet aggregation (SPA) and
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aggregation in response to ADP and collagen. Platelet
flow cytometry was also used to quantify P-selectin
and PAC-1 binding. These patients were recruited
from general surgical outpatient clinics and risk fac-
tors for vascular disease (i.e. smoking, hypertension,
hyperlipidaemia, ischaemic heart disease, diabetes,
IC, carotid disease and AAA) were excluded by his-
tory, clinical examination, routine blood testing,
resting ankle/brachial systolic pressure index (ABPI)
measurements and duplex scanning (ATL HDI 3000
ultrasonic device, Bothell, Wash) (Table 1). Patients on
cardiac, antihypertensive, anticoagulation or anti-
platelet medication were excluded from the control
group.
Twenty patients with documented rest pain or IC
and with a resting ABPI 0.85 were recruited from a
vascular surgical ward and outpatient clinic. Exclu-
sion criteria for all subjects included concomitant
diabetes mellitus, malignant or infectious processes,
venous disease, recent ischaemic cardiovascular
event, significant hepatic or renal disease, and war-
farin or systemic heparin therapy, as these factors
are known to modify platelet function.21 All patients
were on antiplatelet therapy, typically aspirin
(75±150 mg) or dipyridamole (400 mg) for at least
1 month prior to entering the study (Table 1). Forty
consecutive patients awaiting carotid endarterectomy
(CEA) and 13 patients awaiting infra-renal abdominal
aneurysm repair also participated in this study.
All patients gave their informed consent. Approval
was obtained from the local regional ethical
committee.
Blood sampling
All subjects rested supine prior to and during vene-
puncture. Clean peripheral venepuncture was per-
formed with minimal stasis using a 21-gauge
butterfly needle with a double syringe method and
a light tourniquet; conditions designed to minimise
artefactual platelet activation.22 Blood was sampled
from patients awaiting surgery the day before surgery.
On each occasion, the first 3 ml of blood was discarded
and thereafter, 20 ml of blood was collected into a
1/10-vol of 3.8% trisodium citrate anticoagulant for
aggregometry and flow cytometric studies.
Platelet aggregometry
Platelet function in vitro was assessed by platelet
aggregometry using free platelet counting to determine
SPA at 3 min and aggregation induced by ADP (1 mM)
and collagen (1 mg/ml) using a Chronolog model S40
aggregometer (Labmedics, Manchester, U.K.) and a
Coulter T-890 counter (Coulter Electronics, Luton,
U.K.) as previously described.24 Collagen and ADP
were obtained from Sigma Chemicals, Poole, U.K.
Flow cytometric analysis of platelet activation
The methodology for whole blood flow cytometric
assay preparation was as outlined by Shattil et al.
and in accordance with the European working group
Table 1. Baseline characteristics of patients and controls.
Patients Lower limb PAD patients Carotid patients AAA patients Control patients
(n 20) (n 40) (n 13) (n 20)
Median age, years (Range) 61 (55±81) 68 (50±78) 71 (56±81) 68 (50±78)
Sex (M/F) 12/8 30/10 10/3 15/5
Risk factors
Smoking, n (%) 15 (75) 16 (40) 8 (62) 0
High cholesterol, n (%) 10 (50) 12 (30) 1 (8) 0
Hypertension, n (%) 13 (65) 25 (63) 9 (69) 0
Coronary disease, n (%) 12 (60) 13 (33) 8 (62) 0
Medications
Aspirin, n (%) 18 (90) 36 (90) 8 (62) 0
Dipyridamole, n (%) 13 (65) 2 (5) 0 0
Nitrates, n (%) 3 (15) 6 (15) 4 (31) 0
b-blockers, n (%) 5 (25) 12 (30) 9 (69) 0
ACE inhibitor, n (%) 2 (10) 16 (40) 7 (54) 0
PAD Symptoms
Claudication, n (%) 14 (70) 0 0 0
Rest pain, n (%) 6 (30) 0 0 0
Carotid disease
Symptomatic, n (%) 0 35 (88) 0 0
Asymptomatic, n (%) 0 5 (12) 2 0
PADperipheral arterial disease, AAA abdominal aortic aneurysm.
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on cell cycle analysis consensus protocol for the flow
cytometric characterisation of platelet function.22,23
Details of the methodology is described in an earlier
report.24
Antibodies for flow cytometry
The following murine monoclonal antibodies were
used: fluorescein isothiocyanate (FITC) conjugated
PAC-1, peridinin chlorophyll-a protein (PerCP)-
conjugated CD61, FITC conjugated anti-CD42a and
phycoerythrin (PE)-conjugated anti-CD62P. All were
obtained from Becton Dickinson, Oxford, U.K. A dou-
ble staining method was used where platelet samples
were stained with combinations of CD42a/CD62P and
CD61/PAC-1 FITC.
All samples were analsyed within 2 h of preparation
in a Becton Dickinson FACScan flow cytometer. The
platelet population was identified by means of its light
scatter characteristics and data was obtained with gain
settings in the logarithmic mode from 5000 platelets
collected from each sample. The saved list mode files
were then analysed by LYSIS II software (FACScan,
Becton Dickinson Immunocytometry Systems,
Oxford, U.K.). Using two-colour analysis, platelet
events were triggered for cells expressing CD42a
(Gp1b) or CD61PerCP (GpIIb) only. Platelet activation
was measured by determining the percentage of
platelets (CD42a positive events) expressing CD62PE
and the percentage of platelets (CD61 positive events)
expressing PAC-1 FITC.
Statistical analysis
Data analysis was performed using GraphPad Prism
Software. All results are shown as medians with
scatter plots. Differences between the groups were
analysed using the unpaired non-parametric Mann±
Whitney U-test. Differences were considered signifi-
cant at p < 0.05.
Results
Figure 1 shows SPA at 3 min in patients with carotid
disease, AAA and lower limb PAD compared with
normal controls. There was higher baseline SPA in
patients with lower limb PAD (p < 0.01) or AAA
(p < 0.05) compared to normal controls. There was no
significant difference between patients with carotid
disease and normal controls.
Figure 2 shows SPA, ADP (1 mM)- and collagen
(1 mg/mL)-induced platelet aggregation in control
and lower limb PAD patients. There was significantly
higher collagen-induced aggregation in lower limb
PAD patients compared to normal controls (p < 0.01).
However, there was no difference in ADP-induced
aggregation between lower limb PAD and control
patients.
Figure 3 shows the percentage of PAC-1 binding
(specific for the activated form of GpIIb/IIIa) detected
by flow cytometry in control patients and patients
with carotid disease, AAA and lower limb PAD.
There was no difference in PAC-1 binding between
control patients and the patients with lower limb
PAD, carotid disease or AAA.
P-selectin expression detected by flow cytometry is
shown in Figure 4. Patients with carotid disease had
a higher expression of P-selectin compared to nor-
mal controls (p < 0.05). There was no difference in
P-selectin expression between the patients with
lower limb PAD or AAA and normal controls.











Fig. 1. Spontaneous platelet aggregation (SPA) at 3 min in CEA (n 40), AAA (n 13) and lower limb PAD (n 20) patients compared with
normal controls (n 20). Data is shown as medians with scatter plots (p < 0.01, p < 0.001 Mann±Whitney U-test). (CEA carotid
endarterectomy, AAA abdominal aortic aneurysm, PADperipheral arterial disease).
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Fig. 2. Graph of spontaneous platelet aggregation (SPA), ADP- and collagen-induced platelet aggregation in control (n 20) patients
compared with lower limb PAD (n 20) patients. Data is shown as medians with scatter plots (p < 0.01 Mann±Whitney U-test).










Fig. 3. PAC-1 expression (%) in CEA (n 40), AAA (n 13) and lower limb PAD (n 20) patients compared with normal controls (n 20).
Data is shown as medians with scatter plots (pnot significant, Mann±Whitney U-test). (CEA carotid endarterectomy, AAA abdominal
aortic aneurysm, PADperipheral arterial disease).









Fig. 4. P-selectin expression (%) in CEA (n 40), AAA (n 13) and lower limb PAD (n 20) patients compared with normal controls
(n 20). Data is shown as medians with scatter plots (p < 0.05 Mann±Whitney U-test). (CEA carotid endarterectomy, AAA abdominal
aortic aneurysm, PADperipheral arterial disease).
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Discussion
This study has shown that patients with lower limb
PAD or AAA have a higher degree of platelet aggre-
gration in vivo compared to normal age- and sex-
matched controls. This was not seen in patients with
carotid disease and may reflect the greater extent of
atherosclerotic disease in patients with lower limb
PAD and AAA. These differences were demonstrated
despite patients with PAD taking antiplatelet therapy
mainly in the form of aspirin. When ADP or collagen
were used in small concentrations, there was greater
agonist-induced aggregation in patients with PAD
compared to controls. This has important implications
in patients with PAD undergoing angioplasty or any
surgical procedure where intimal damage is pro-
duced. This would expose the subendothelial matrix
to hyperactive platelets and trigger the sequence of
platelet adhesion and activation. These patients might
then be at increased risk of thrombosis or embolic
complications.
Patients with carotid disease had higher P-selectin
expression but not PAC-1 binding (which indicates
activation of the GPIIb/IIIa receptor). Most of these
patients had been recently symptomatic from their
carotid disease and this may explain the higher
expression of platelet P-selectin since Grau et al. have
previously shown an increased fraction of circulating
activated plasma P-selectin in acute and previous
cerebrovascular ischaemia.3 There was no difference
in PAC-1 binding or P-selectin expression in patients
with lower limb PAD or AAA compared to normal
controls. This may be due to the reversible expression
of some or all of the surface neoepitopes associated
with the platelet activation. Surface expressed P-selectin
is rapidly cleaved to release soluble P-selectin into the
plasma.25 Thus, the levels of P-selectin on the platelet
surface may not be a true reflection of the in vivo
activation state of the circulating platelets. Several
clinical studies have demonstrated elevated plasma
levels of soluble P-selectin associated with acute
and chronic atherosclerotic syndromes including
PAD.26±30
Galt et al. have also compared platelet function in
patients with severe PAD and age-matched controls.31
Like us no they found no difference in baseline
P-selectin expression between PAD and healthy
age-matched control subjects.31 However, since a-
degranulation is a late event in the process of platelet
activation, P-selectin expression may be a late marker
of platelet activation. In contrast to the findings of Galt
et al., we found that whole blood platelet aggregation
was significantly enhanced in PAD patients. This dif-
ference may be explained by the use of whole blood
methods to study platelet aggregation and avoiding
the limitations described with using PRP.32,33
The results of SPA and agonist-induced aggregation
in lower limb PAD patients in this study suggest that
these circulating platelets maintain a heightened acti-
vation status. It may be inferred that these platelets
possess a lower threshold for aggregation. There are a
number of possible explanations for this hyperacti-
vated status despite the use of aspirin. Firstly, it
may be a consequence of multilevel atherosclerosis
inducing platelet activation through increased shear
stresses generated at sites of arterial stenosis or via
elevated plasma concentrations of platelet agonists
secondary to platelet-plaque interactions.34,35 Secondly,
it may reflect the influence of risk factors such as
smoking, type IIa hypercholesterolaemia or hyperten-
sion which by themselves persistently activate plate-
lets. Davi et al. provide data suggesting that the
metabolic and haemodynamic disturbances exerted
by these risk factors and not diffuse atherosclerotic
lesions per se provide the major triggers of persistent
platelet activation in PAD.36 Thirdly, it is possible that
this hyperactivated status may result from the
increased presence of larger, younger reticulated
platelets in PAD as a result of increased consumption
at the level of the atherosclerotic plaque. Increased
reticulated platelet counts have been demonstrated
in some conditions associated with hyperactivated
platelets and these reticulated platelets have been
shown to be hypereactive.37±39 Finally it may be that
a proportion of these patients have platelets which are
relatively resistant to aspirin.20 Unfortunately, the pre-
sent study was not designed to identify the relative
contributions of these mechanisms but platelet hyper-
activation in PAD is most likely to result from a com-
plex combination of these factors.
Platelet inhibition is not a uniform process. In this
study platelet aggregation was increased in PAD
patients despite the use of aspirin. Only some aspects
of platelet activity are inhibited by aspirin which acts
mainly on endoperoxide synthesis, reducing TXA2
release from platelets.40 In contrast, ticlopidine and
clopidogrel inhibit ADP-induced platelet aggregation,
which is a relatively aspirin resistant process.41 Clopi-
dogrel also inhibits platelet aggregation induced by
thrombin, TXA2 and collagen.41,42 This multiplicity of
actions reflects the central role of ADP (released from
activated platelets) in mediating and amplifying the
aggregation induced by several agonists.
In summary, the results of the current study suggest
there may be a group of patients with significant
platelet hyperactivation prior to any intervention despite
being on aspirin. These patients may be at higher risk
of thromboembolic complications. The increased
20 P. A. Robless et al.
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effectiveness of clopidogrel compared to aspirin in the
CAPRIE study may be related to its inhibition of ADP-
induced platelet aggregation.14 This form of platelet
activation may be important in PAD and may explain
the observed aspirin resistance in these patients. Since
TXA2 and ADP contribute to thrombogenesis, simul-
taneous inhibition of the two pathways, with clopido-
grel plus aspirin, might add significantly to the
proven benefit of aspirin alone. Evidence of the effi-
cacy of the combination of aspirin and ticlopidine or
clopidogrel has recently been found in recent trials of
patients undergoing coronary stenting.43±45 Similar
clinical studies in PAD are still awaited.
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